Sponsors and Exhibitors

Platinum Sponsors

Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. Our medicines are helping millions of patients around the world in their fight against cancer, cardiovascular disease, hepatitis C, HIV and rheumatoid arthritis.
Since 2009, we have delivered 12 new products to patients with serious diseases. Four of these are biologic products, including groundbreaking immunotherapies that use the body’s immune system to fight cancer. Additional biologic compounds – as well as scores of other investigational medicines – are advancing through the development pipeline. We are recognized as having one of the most productive R&D pipelines in the industry.
What sets us apart as a BioPharma leader is our commitment to helping patients prevail over serious diseases and our focus on finding innovative medicines to combat those diseases.
Generating new ideas and thinking differently are at the heart of everything we do – making a difference in the lives of patients.
MSD
For 125 years, MSD has been a global health care leader working to help the world be well. MSD is a tradename of Merck & Co., Inc., Kenilworth, N.J., USA. Through our prescription medicines, vaccines, biologic therapies, and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships. For more information, visit www.msd.com.


About Roche
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives.
Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.
Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. Twenty-nine medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry seven years in a row by the Dow Jones Sustainability Indices.
The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2015 employed more than 91,700 people worldwide. In 2015, Roche invested CHF 9.3 billion in R&D and posted sales of CHF 48.1 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.


Gold Sponsors

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics. World-class science and the pursuit of R&D excellence drive Incyte’s business and its commitment to improving the lives of patients with cancer and other diseases.  
Incyte has a broad and diverse clinical portfolio that includes 14 development candidates against 11 different molecular targets.
Headquartered in Wilmington, Delaware, Incyte Corporation has operations in Switzerland and eight other European countries. For more information, visit www.incyte.com. Follow @Incyte on Twitter at https://twitter.com/Incyte.
About LEO Pharma
LEO Pharma helps people achieve healthy skin. By offering care solutions to patients in more than 100 countries globally, LEO Pharma supports people in managing their skin conditions.
Founded in 1908 and owned by the LEO Foundation, the healthcare company has devoted decades of research and development to delivering products and solutions to people with skin conditions.
LEO Pharma is headquartered in Denmark and employs around 5,000 people worldwide.
For more information, visit www.leo-pharma.com
Subscribe to our YouTube channel: www.youtube.com/leopharmaglobal
Follow us on Twitter: www.twitter.com/leohealthyskin
Visit us at LinkedIn: www.linkedin.com/company/leo-pharma

About Merck-Pfizer Alliance
Immuno-oncology is a top priority for Merck and Pfizer. The global strategic alliance between Merck and Pfizer enables the companies to benefit from each other’s strengths and capabilities and further explore the therapeutic potential of avelumab, an investigational anti-PD-L1 antibody initially discovered and developed by Merck. The immuno-oncology alliance will jointly develop and commercialize avelumab and advance Pfizer’s PD-1 antibody. The alliance is focused on developing high-priority international clinical programs to investigate avelumab, as a monotherapy, as well as combination regimens, and is striving to find new ways to treat cancer.

Silver Sponsors

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.
Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people’s lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world’s leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
For more information, visit www.amgen.com and follow us on www.twitter.com/amgen.
Novartis Group has a leading position in the Greek Pharmaceuticals Sector. It has been active in Greece for more than 20 years, with a diversified portfolio including innovative medicines (Novartis), holistic eye care (Alcon) and generics (Sandoz). Novartis' portfolio includes more than 50 innovative products, many of which are leaders in therapeutic areas such as cardiometabolic diseases, the Immunology and Dermatology, the Neurosciences, the respiratory disease, Ophthalmology, Oncology and Haematology.
In Novartis we are inspired by patients and we focus our Corporate Responsibility work in two key areas: expanding access to healthcare and doing business responsibly.We utilize science-based innovation to deliver better patient outcomes. Our vision is to contribute to the evolution of medical practice, always with high levels of responsibility and integrity.
In the period 2013-2015 the company invested 138.2 mio Euros in Greek society, through R & D, tax payments, payroll, suppliers, donations and sponsorships, while our investments to approximately 200 clinical trials is more than 18 mio. Euros.
We support patients by implementing innovative programs to improve their quality of life and their survival expectancy, in collaboration with scientific and patient community. We consistently support social and scientific initiatives such as drug donations, free medical exams, early access programs to innovative treatments, donations to Public Hospitals and University Clinics for conducting scientific research programs, Also we realize disease awareness and prevention programs, patient rights campaigns and support many patient associations.
About Takeda Pharmaceutical Company
Takeda Pharmaceutical Company Limited is a global, research and development-driven pharmaceutical company committed to bringing better health and a brighter future to patients by translating science into life-changing medicines. Takeda focuses its R&D efforts on oncology, gastroenterology and central nervous system therapeutic areas plus vaccines. Takeda conducts R&D both internally and with partners to stay at the leading edge of innovation. New innovative products, especially in oncology and gastroenterology, as well as our presence in Emerging Markets, fuel the growth of Takeda. More than 30,000 Takeda employees are committed to improving quality of life for patients, working with our partners in health care in more than 70 countries.
Additional information about Takeda is available through its corporate website, www.Takeda.com.
Bronze Sponsors

Norgine is a leading European specialist pharmaceutical company with a direct commercial presence in all major European markets. In 2016 the company generated product sales of approximately €300 million, as well as significant royalty and milestone income.
Norgine specialises in gastroenterology, hepatology, cancer and supportive care. Norgine is active in the field of sentinel node detection in breast cancer, melanoma and oral squamous cell carcinoma.
Norgine employs over 1,000 people across its commercial, development and manufacturing operations and manages all aspects of product development, production, marketing, sale and supply.
Norgine is headquartered in the Netherlands. Norgine owns a R&D site in Hengoed, Wales and two manufacturing sites in Hengoed, Wales and Dreux, France.
For more information, please visit www.norgine.com
NORGINE and the sail logo are trademarks of the Norgine group of companies
About Pierre Fabre (January 2017)
Pierre Fabre is the 2nd largest dermo-cosmetics laboratory in the world and the 2nd largest private French pharmaceutical group. In 2015, it generated 2,208 million euros in net sales, of which 58% came from its international business and 57% from its dermo-cosmetics division. Pierre Fabre, which has always been headquartered in the South-West of France, owns subsidiaries in 43 countries, enjoys distribution agreements in over 130 countries and counts around 13,000 employees worldwide. Pierre Fabre’s portfolio represents a continuum of activities spanning from prescription drugs and consumer health care products to dermo-cosmetics.
In 2015, Pierre Fabre dedicated almost 200 million euros to R&D, shared between oncology, dermatology, the central nervous system, consumer health care and dermo-cosmetics. With its brands, Eau Thermale Avène, Klorane, Ducray, René Furterer, A-Derma, Galénic, Elancyl, Pierre Fabre Health Care, Pierre Fabre Oral Care and Naturactive, Pierre Fabre is the market leader in France for skin care, hair care and oral care products sold in pharmacies and drugstores. Marketed globally, Eau Thermale Avène is the leading dermo-cosmetics brand in Europe and in Asia. In oncology, Pierre Fabre generates over 90% of its revenue outside France.
Pierre Fabre is mostly owned (86%) by the Pierre Fabre Foundation, a government-recognized public-interest foundation, and secondarily by its own employees.


Exhibitors & Sponsors